Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis
| Autor: | He He, Lin Zhang, Shenling Liao, Mei Zhang, Zhi Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Funnel plot Cochrane Library Overweight Placebo 030226 pharmacology & pharmacy law.invention Body Mass Index 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Obesity Randomized Controlled Trials as Topic Pharmacology business.industry Body Weight General Medicine Publication bias Lipids Clinical trial Mental Health Cardiovascular Diseases Meta-analysis Anti-Obesity Agents medicine.symptom business |
| Zdroj: | European journal of clinical pharmacology. 77(11) |
| ISSN: | 1432-1041 |
| Popis: | Anti-obesity therapy can reduce body weight; however, it is not clear whether it can reduce major adverse cardiovascular events (MACEs). We conducted a systematic review and meta-analysis to assess the effect of long-term anti-obesity drugs on MACEs in individuals with overweight or obesity. The MEDLINE, Embase, and Cochrane Library databases and clinical trial registries ( https://clinicaltrials.gov ) were searched up to 3 May 2021 for randomized controlled trials (RCT) that compared anti-obesity drugs with controls and reported cardiovascular events in subjects with overweight or obesity. Heterogeneity was described by the I2 value. The Mantel–Haenszel randomized effects model was adopted to calculate risk ratios (RR) and weighted mean differences (WMD). Sensitivity analysis was used to assess the stability of the effects. Publication bias was assessed by Begg's funnel plot and Egger's test. The Cochrane Collaboration risk-of-bias tool was used to evaluate the bias of each included RCT. Twelve articles were included; 21,391 and 17,618 subjects were in the anti-obesity drug and placebo groups, respectively. There was no difference in MACEs between the anti-obesity drug and placebo groups (RR 0.99; 95% CI: 0.88–1.12). Compared with placebo, anti-obesity interventions reduced body weight (WMD: − 3.96 kg; 95% CI: − 4.89, − 3.03) and improved lipid and blood glucose profiles. The intervention also did not increase the incidence of depression or anxiety or the risk of suicidal ideation. Long-term anti-obesity drugs did not show a benefit in lowering MACEs in overweight or obese subjects, although the drugs resulted in a decrease in body weight and improved cardiometabolic parameters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink